EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudie

Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis

Taylor D Steuber iD, Thomas Rosandich, Tiffany Cadwallader, Lauren Steil, Madeline Belk, Usha Yendrapalli, Ali Hassoun, Jonathan Edwards

Annals of Pharmacotherapy · 2024

DOI: 10.1177/10600280231190401 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Taylor D Steuber und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Missouri-Kansas City, Columbia, MO, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, COVID-19, COVID-19 Drug Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tocilizumab may reduce the risk of death, length of stay, and time of mechanical ventilation in patients hospitalized with COVID-19. Limited data are available evaluating low-dose subcutaneous administration of tocilizumab in this setting.

Objective

To compare outcomes of 2 tocilizumab dosing and administration strategies in patients hospitalized with COVID-19.

Methods

A retrospective, observational cohort study was conducted to compare clinical outcomes in patients hospitalized with COVID-19 receiving tocilizumab 400 mg intravenously (400 mg IV) or 162 mg subcutaneously (162 mg SC). Hospitalized patients receiving a single dose of tocilizumab were eligible for inclusion and grouped by dosing and administration strategy. The primary endpoint was ventilator-free days at day 28. Secondary endpoints included length of stay (LOS), intensive care unit (ICU) LOS, mechanical ventilation required after dose, 28-day readmission, 28-day mortality, and change in inflammatory markers.

Results

A total of 303 patients were included, with 147 who received tocilizumab 400 mg IV and 156 who received 162 mg SC. There was no significant difference in average ventilator-free days at day 28 in patients receiving 400 mg IV compared with 162 mg SC (26.4 ± 5.3 vs 25.6 ± 6.8 days, respectively; P = 0.812). There was also no difference in LOS (10.4 ± 12.6 vs 10.5 ± 14.0 days; P = 0.637), ICU LOS (3.9 ± 9.0 vs 3.5 ± 8.3 days; P = 0.679), mechanical ventilation after dose (15.6% vs 19.2%; P = 0.412), 28-day readmission (6.1% vs 9.6%; P = 0.268), or 28-day mortality (23.1% vs 25.6%; P = 0.611). Finally, there was no difference regarding change in inflammatory markers at 48 hours ( P > 0.05 for all interactions). Conclusion and Relevance: In this retrospective study involving hospitalized patients with COVID-19, there was no difference between tocilizumab 162 mg SC and 400 mg IV in terms of efficacy. The 162 mg SC dose may be a reasonable alternative to traditional doses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCOVID-19COVID-19 Drug TreatmentHumansRespiration, ArtificialRetrospective StudiesSARS-CoV-2Treatment OutcomeInjections, SubcutaneousHospitalizationMaleFemaleMiddle AgedAged

Stichwörter der Autor:innen

COVID-19SARS-CoV-2dosinginterleukin-6 receptor antagonisttocilizumab

Substanzen

Antibodies, Monoclonal, Humanizedtocilizumab

Autor:innen und Institutionen

  • School of Pharmacy, University of Missouri-Kansas City, Columbia, MO, USA.
  • Harrison College of Pharmacy, Auburn University, Auburn, AL, USA.
  • Department of Pharmacy, Huntsville Hospital, Huntsville, AL, USA.
  • Department of Internal Medicine, Huntsville Hospital, Huntsville, AL, USA.
  • Alabama Infectious Disease Center, Huntsville, AL, USA.

ORCID-Profile: Taylor D Steuber

Zitieren

APA

Steuber, T. D., Rosandich, T., Cadwallader, T., Steil, L., Belk, M., Yendrapalli, U., Hassoun, A., & Edwards, J. (2024). Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231190401

Vancouver

Steuber TD, Rosandich T, Cadwallader T, Steil L, Belk M, Yendrapalli U, et al. Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231190401

BibTeX
@article{Steuber2024,
  author = {Steuber, Taylor D and Rosandich, Thomas and Cadwallader, Tiffany and Steil, Lauren and Belk, Madeline and Yendrapalli, Usha and Hassoun, Ali and Edwards, Jonathan},
  title = {Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis},
  journal = {Annals of Pharmacotherapy},
  year = {2024},
  doi = {10.1177/10600280231190401}
}
Kostenlos starten →